Salix's AIDS/HIV-related diarrhea drug Fulyzaq gets FDA nod

01/1/2013 | Reuters · American City Business Journals

Salix Pharmaceuticals' Fulyzaq, or crofelemer, has been approved by the FDA to treat diarrhea in HIV/AIDS patients undergoing antiretroviral therapy. This makes Fulyzaq, developed by Napo Pharmaceuticals, the first approved treatment for HIV/AIDS patients whose diarrhea is not caused by bacteria, virus or parasite.

View Full Article in:

Reuters · American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC